Ontology highlight
ABSTRACT:
SUBMITTER: Batchelor TT
PROVIDER: S-EPMC4021043 | biostudies-literature | 2013 Sep
REPOSITORIES: biostudies-literature
Batchelor Tracy T TT Mulholland Paul P Neyns Bart B Nabors L Burt LB Campone Mario M Wick Antje A Mason Warren W Mikkelsen Tom T Phuphanich Surasak S Ashby Lynn S LS Degroot John J Gattamaneni Rao R Cher Lawrence L Rosenthal Mark M Payer Franz F Jürgensmeier Juliane M JM Jain Rakesh K RK Sorensen A Gregory AG Xu John J Liu Qi Q van den Bent Martin M
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20130812 26
<h4>Purpose</h4>A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma.<h4>Patients and methods</h4>Patients (N = 325) with recurrent glioblastoma who previousl ...[more]